Evidence map›Paper›PMID 34385149›Full record

ArticleBMJ open respiratory research2021

Prevalence and significance of pulmonary disease on lung ultrasonography in outpatients with SARS-CoV-2 infection.

Robert M Fairchild, Audra Horomanski, Diane A Mar, Gabriela R Triant, Rong Lu, Di Lu, Haiwei Henry Guo, Matthew C Baker

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Robert M Fairchild *Department of Immunology & Rheumatology, Stanford University, Stanford, California, USA rfairchi@stanford.edu.
Audra Horomanski *Department of Immunology & Rheumatology, Stanford University, Stanford, California, USA.ORCID 0000-0002-5084-4389
Diane A MarDepartment of Immunology & Rheumatology, Stanford University, Stanford, California, USA.
Gabriela R TriantDepartment of Immunology & Rheumatology, Stanford University, Stanford, California, USA.
Rong LuQuantitative Sciences Unit, Division of Biomedical Informatics Research, Stanford University, Stanford, California, USA.
Di LuQuantitative Sciences Unit, Division of Biomedical Informatics Research, Stanford University, Stanford, California, USA.
Haiwei Henry GuoDepartment of Radiology, Stanford University, Stanford, California, USA.
Matthew C BakerDepartment of Immunology & Rheumatology, Stanford University, Stanford, California, USA.
Stanford University · US

Funding

Stanford TRANSFORM I2T ProgramR25AI147369 · NIAID · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW, SINGH, UPINDER · 2019 to 2023
$1.8M
NIAID NIH HHS R25 AI147369
6 · The paper itself

Abstract

backgroundThe majority of patients with SARS-CoV-2 infection are diagnosed and managed as outpatients; however, little is known about the burden of pulmonary disease in this setting. Lung ultrasound (LUS) is a convenient tool for detection of COVID-19 pneumonia. Identifying SARS-CoV-2 infected outpatients with pulmonary disease may be important for early risk stratification.

objectivesTo investigate the prevalence, natural history and clinical significance of pulmonary disease in outpatients with SARS-CoV-2.

methodsSARS-CoV-2 PCR positive outpatients (CV(+)) were assessed with LUS to identify the presence of interstitial pneumonia. Studies were considered positive based on the presence of B-lines, pleural irregularity and consolidations. A subset of patients underwent longitudinal examinations. Correlations between LUS findings and patient symptoms, demographics, comorbidities and clinical outcomes over 8 weeks were evaluated.

results102 CV(+) patients underwent LUS with 42 (41%) demonstrating pulmonary involvement. Baseline LUS severity scores correlated with shortness of breath on multivariate analysis. Of the CV(+) patients followed longitudinally, a majority showed improvement or resolution in LUS findings after 1-2 weeks. Only one patient in the CV(+) cohort was briefly hospitalised, and no patient died or required mechanical ventilation.

conclusionWe found a high prevalence of LUS findings in outpatients with SARS-CoV-2 infection. Given the pervasiveness of pulmonary disease across a broad spectrum of LUS severity scores and lack of adverse outcomes, our findings suggest that LUS may not be a useful as a risk stratification tool in SARS-CoV-2 in the general outpatient population.

Indexed as

COVID-19HumansLungLung DiseasesOutpatientsPrevalenceUltrasonographyCOVID-19imaging/CT MRI etcpneumonia

Identifiers

PMID34385149
PMCPMC8361701
OpenAlexW3187688376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.